(Q33869357)

29 July 2017

1 reference

title

Radioimmunotherapy: designer molecules to potentiate effective therapy (English)

1 reference

29 July 2017

Milenic DE

1

1 reference

29 July 2017

publication date

1 April 2000

1 reference

Seminars in Radiation Oncology

29 July 2017

published in

1 reference

29 July 2017

volume

10

1 reference

29 July 2017

issue

2

1 reference

29 July 2017

page(s)

139-155

1 reference

Continuous cultures of fused cells secreting antibody of predefined specificity

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980051-X

7 January 2021

Phase-I/II radio-immunotherapy study with Iodine-131-labeled anti-CEA monoclonal antibody F6 F(ab')2 in patients with non-resectable liver metastases from colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980051-X

7 January 2021

Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I/II study

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980051-X

7 January 2021

Current status of radioimmunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980051-X

7 January 2021

High-dose therapy with iodine-131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers: a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980051-X

7 January 2021

Radioimmunotherapy of athymic mice bearing human colon carcinomas with monoclonal antibody B72.3: histological and autoradiographic study of effects on tumors and normal organs

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980051-X

7 January 2021

Antiidiotypic response against murine monoclonal antibodies reactive with tumor-associated antigen TAG-72

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980051-X

7 January 2021

Repeated antitumour antibody therapy in man with suppression of the host response by cyclosporin A.

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980051-X

7 January 2021

Phase I/II trial of (131)I-MN-14F(ab)2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980051-X

7 January 2021

Radioimmunotherapy of metastatic colorectal tumours with iodine-131-labelled antibody to carcinoembryonic antigen: phase I/II study with comparative biodistribution of intact and F(ab')2 antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980051-X

7 January 2021

Comparison of methods for the generation of immunoreactive fragments of a monoclonal antibody (B72.3) reactive with human carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980051-X

7 January 2021

Comparative pharmacokinetic properties of murine monoclonal antibody A7 modified with neocarzinostatin, dextran and polyethylene glycol.

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980051-X

7 January 2021

Production of antibodies in transgenic plants

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980051-X

7 January 2021

Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980051-X

7 January 2021

Replacing the complementarity-determining regions in a human antibody with those from a mouse

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980051-X

7 January 2021

Anatomy of the antibody molecule

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980051-X

7 January 2021

Three-dimensional structure of an antigen-antibody complex at 2.8 A resolution

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980051-X

7 January 2021

Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49.

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980051-X

7 January 2021

90Yttrium-labeled complementarity-determining-region-grafted monoclonal antibodies for radioimmunotherapy: radiolabeling and animal biodistribution studies

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980051-X

7 January 2021

Reshaping human antibodies for therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980051-X

7 January 2021

CDR substitutions of a humanized monoclonal antibody (CC49): contributions of individual CDRs to antigen binding and immunogenicity

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980051-X

7 January 2021

Aglycosylated chimeric mouse/human IgG1 antibody retains some effector function

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980051-X

7 January 2021

Biologic properties of a CH2 domain-deleted recombinant immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980051-X

7 January 2021

A CDR-grafted (humanized) domain-deleted antitumor antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980051-X

7 January 2021

Comparative biological properties of a recombinant chimeric anti-carcinoma mAb and a recombinant aglycosylated variant

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980051-X

7 January 2021

Breast cancer imaging with radiolabelled peptide from complementarity-determining region of antitumour antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980051-X

7 January 2021

Assembly of a functional immunoglobulin Fv fragment in Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980051-X

7 January 2021

A comparison of strategies to stabilize immunoglobulin Fv-fragments

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980051-X

7 January 2021

Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980051-X

7 January 2021

Single-chain antigen-binding proteins

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980051-X

7 January 2021

In vivo tumor targeting of a recombinant single-chain antigen-binding protein

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980051-X

7 January 2021

Radioimmunotherapy with alpha-emitting nuclides

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980051-X

7 January 2021

Conformational stability, folding, and ligand-binding affinity of single-chain Fv immunoglobulin fragments expressed in Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980051-X

7 January 2021

An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability.

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980051-X

7 January 2021

Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980051-X

7 January 2021

Pharmacokinetics and biodistribution of radioimmunoconjugates of anti-CD19 antibody and single-chain Fv for treatment of human B-cell malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980051-X

7 January 2021

A form of anti-Tac(Fv) which is both single-chain and disulfide stabilized: comparison with its single-chain and disulfide-stabilized homologs

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980051-X

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980051-X

7 January 2021

Tumor localization of anti-CEA single-chain Fvs: improved targeting by non-covalent dimers

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980051-X

7 January 2021

Binding characteristics and tumor targeting of a covalently linked divalent CC49 single-chain antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980051-X

7 January 2021

Production and characterization of an anti-(MUC1 mucin) recombinant diabody

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980051-X

7 January 2021

Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980051-X

7 January 2021

Triabodies: single chain Fv fragments without a linker form trivalent trimers

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980051-X

7 January 2021

'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980051-X

7 January 2021

Miniantibodies: use of amphipathic helices to produce functional, flexibly linked dimeric FV fragments with high avidity in Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980051-X

7 January 2021

Charge-modified single chain antibody constructs of monoclonal antibody CC49: generation, characterization, pharmacokinetics, and biodistribution analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980051-X

7 January 2021

Bifunctional antibodies for radioimmunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980051-X

7 January 2021

Two-step tumour targetting in ovarian cancer patients using biotinylated monoclonal antibodies and radioactive streptavidin

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980051-X

7 January 2021

Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin.

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980051-X

7 January 2021

10.1016/S1053-4296(00)80051-X

Identifiers

DOI

1 reference

29 July 2017

1 reference